MedTrace Logo

Investigation of Intranasal Ketamine Related Changes in Attentional Brain Networks With Functional and Structural MRI

NCT05320120 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-04-15

No results posted yet for this study

Summary

Subanesthetic ketamine is currently used as a rapid-acting antidepressant. It is an antagonist of the N-methyl-d-aspartate (NMDA) receptor, but former results indicate that its action also depends on the noradrenaline system and the locus coeruleus (LC).

Based on this known impact of ketamine on the sympathetic nervous system the aim of this study is to investigate the effects of intranasal esketamine on LC related attentional brain networks in task based functional MRI, to relate those attention network changes to behavioural measures and to predict ketamine related attention network changes by brain structure.

Conditions

  • Ketamine Treatment

Interventions

DRUG

56mg esketamine (2x Spravato® 28 mg nasal spray)

56mg esketamine (2x Spravato® 28 mg nasal spray)

DRUG

0.9% saline solution nasal spray

0.9% saline solution nasal spray

Sponsors & Collaborators

  • Rupert Lanzenberger

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-06-21
Completion
2023-06-21

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05320120 on ClinicalTrials.gov